The transition through menopause triggers complex metabolic changes in women. Doctors must evaluate HRT and cardiometabolic risk to ensure safe treatment plans. Recent research highlights how hormone therapy impacts visceral fat, blood pressure, and lipid profiles.
Understanding HRT and Cardiometabolic Risk Factors
Starting hormone replacement therapy early provides significant benefits for most patients. Specifically, initiating treatment within ten years of menopause often improves heart health outcomes. This window of opportunity allows the body to maintain vascular flexibility. Furthermore, the route of administration plays a critical role in metabolic safety. Transdermal estrogen typically offers a safer profile for women with high blood pressure. This delivery method avoids the first-pass metabolism in the liver. Thus, it minimizes the risk of blood clots compared to oral tablets.
Addressing MASLD and Long-term Health
Metabolic dysfunction-associated steatotic liver disease (MASLD) is becoming a major focus for Indian clinicians. Menopause increases the risk of liver fat accumulation significantly due to estrogen loss. However, new studies indicate that HRT may reduce the risk of adverse liver outcomes. Therefore, physicians should consider liver health during every menopausal consultation. Consequently, personalized regimens help mitigate cardiovascular events like stroke or coronary heart disease. Instead of a one-size-fits-all approach, doctors must tailor the dosage and type. This careful selection ensures the best possible long-term metabolic protection for the patient.
Frequently Asked Questions
Q1: Does HRT help prevent metabolic liver disease?
Recent data suggests that HRT can lower the risk of major adverse liver outcomes in perimenopausal women. It specifically helps reduce hepatic fat deposition and inflammation.
Q2: Is HRT safe for women with high blood pressure?
Yes, HRT is not contraindicated for women with hypertension if it is well-controlled. Transdermal delivery is usually preferred to minimize any potential impact on blood pressure levels.
References
- Dong J et al. Hormone Replacement Therapy for Menopausal Symptoms and the Risk of Cardiometabolic Disease: Current Evidence and Future Directions. BJOG. 2026 Mar 11. doi: 10.1111/1471-0528.70214. PMID: 41808572.
- Meeta M et al. Clinical Practice Guidelines on Menopause: 2020 Update. Journal of Mid-life Health.
- The North American Menopause Society. The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022.